Form 4 for ELUT ELUTIA INC.
Accepted 2024-07-31 00:00:00 ET · period of report 2024-07-31 · accession 0001415889-24-020441 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-07-31 | 2024-07-31 | ELUT | Ferguson Matthew | CFO | M - OptEx | $1.43 | +105.1K | 257.8K | +69% | +$150.3K |
| D | 2024-07-31 | 2024-07-31 | ELUT | Ferguson Matthew | CFO | M - OptEx | $0.00 | -105.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-07-31 | M | A | 105,080 | $1.43 | 257,823 | D | — | — | (F1) Transaction represents shares of the Issuer's Class A Common Stock received from the exercise of the warrant dated September 21, 2023. |
| 2 | Derivative | Warrants (rights to buy) | 2024-07-31 | M | D | 105,080 | $0.00 | 0 | D | $1.43 · 2023-09-21 to — | 105,080 Class A Common Stock | (F2) The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028. |